CorVel Corp
NASDAQ:CRVL

Watchlist Manager
CorVel Corp Logo
CorVel Corp
NASDAQ:CRVL
Watchlist
Price: 55.93 USD -1.46%
Market Cap: $2.9B

EV/EBIT

19.2
Current
52%
Cheaper
vs 3-y average of 40.2

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
19.2
=
Enterprise Value
$2.3B
/
EBIT
$136.7m

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
19.2
=
Enterprise Value
$2.3B
/
EBIT
$136.7m

Valuation Scenarios

CorVel Corp is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (40.2), the stock would be worth $116.98 (109% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+109%
Average Upside
50%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 19.2 $55.93
0%
3-Year Average 40.2 $116.98
+109%
5-Year Average 36.3 $105.61
+89%
Industry Average 19.2 $55.96
+0%
Country Average 19.6 $57.05
+2%

Forward EV/EBIT
Today’s price vs future ebit

Not enough data available to calculate forward EV/EBIT

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
US
CorVel Corp
NASDAQ:CRVL
2.9B USD 19.2 27.1
US
CVS Health Corp
NYSE:CVS
100.2B USD 14.2 55.9
US
Cigna Group
XMUN:CGN
68.5B EUR 10 13.5
US
Cigna Corp
NYSE:CI
73.7B USD 0 12.1
DE
Fresenius Medical Care AG
XMUN:FME
23.1B EUR 16.8 23.6
DE
Fresenius SE & Co KGaA
XETRA:FRE
22.9B EUR 13.7 17.9
US
Quest Diagnostics Inc
NYSE:DGX
22.1B USD 15.9 21.6
US
Laboratory Corporation of America Holdings
NYSE:LH
21.8B USD 17.3 24.8
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
10.9B EUR 9.8 11.1
US
Guardant Health Inc
NASDAQ:GH
11.5B USD -27.4 -27.6
US
DaVita Inc
NYSE:DVA
10.6B USD 9.7 13.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
CorVel Corp
NASDAQ:CRVL
Average EV/EBIT: 14.1
19.2
N/A N/A
US
CVS Health Corp
NYSE:CVS
14.2
22%
0.6
US
C
Cigna Group
XMUN:CGN
10
5%
2
US
Cigna Corp
NYSE:CI
Not Available N/A N/A
DE
Fresenius Medical Care AG
XMUN:FME
16.8
11%
1.5
DE
Fresenius SE & Co KGaA
XETRA:FRE
13.7
12%
1.1
US
Quest Diagnostics Inc
NYSE:DGX
15.9
9%
1.8
US
Laboratory Corporation of America Holdings
NYSE:LH
17.3
18%
1
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
9.8
11%
0.9
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -27.4 N/A N/A
US
DaVita Inc
NYSE:DVA
9.7
5%
1.9

Market Distribution

In line with most companies in the United States of America
Percentile
49th
Based on 8 638 companies
49th percentile
19.2
Low
0 — 13.6
Typical Range
13.6 — 27.8
High
27.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 13.6
Median 19.6
70th Percentile 27.8
Max 1 826 183.2

CorVel Corp
Glance View

In the intricate world of healthcare management, CorVel Corporation stands as a pivotal player, harmonizing technology and service to streamline the complexities of risk management and cost containment. Founded in 1987, CorVel has relentlessly pursued the mission of enhancing workplace injury claims processes, reducing expenses while ensuring quality care for the injured. The company's foundation is built on its ability to provide innovative solutions through advanced technology platforms that automate and optimize the management of workers’ compensation, liability claims, and healthcare services. By integrating data analytics, artificial intelligence, and cutting-edge claims management software, CorVel enables employers, insurers, and third-party administrators to keep a tight rein on costs and improve outcomes through proactive decision-making and efficient service delivery. CorVel’s revenue model is intricately tied to its suite of diversified services. The company generates income through its extensive offerings in network solutions, bill review, case management, and pharmacy benefit management. Network solutions form the backbone, providing clients with access to a broad network of medical providers while negotiating favorable rates. Meanwhile, their robust bill review system ensures that every medical claim is scrutinized for accuracy and compliance, a process that helps clients avoid overpayments and recover funds. Case management services further augment their revenue, as skilled professionals facilitate rehabilitation efforts, coordinate care, and monitor recovery progress to encourage cost savings. Moreover, the pharmacy benefit management branch secures additional profit by optimizing prescription costs and improving medication adherence. Together, these services create a seamless ecosystem where CorVel captures significant value through efficiency gains and cost control, solidifying its position in the competitive healthcare management landscape.

CRVL Intrinsic Value
50.39 USD
Overvaluation 10%
Intrinsic Value
Price $55.93
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett